Clinical trials
Relapsed or Refractory B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,718 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06674265RecruitingPhase 1
Natural killer cells for advanced neuroblastoma
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
TehranAges 2–16 - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07181941RecruitingPhase 1/Phase 2
Testing lower doses of linvoseltamab for multiple myeloma
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Seattle, WashingtonAges 18 years+ - NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT06034561RecruitingPhase 2
Bortezomib for relapsed or refractory acute lymphoblastic leukemia
This trial tests a chemotherapy combination that includes bortezomib for people whose acute lymphoblastic leukemia (ALL) has come back or not responded to previous treatments. It aims to offer a new option for those who haven't tried bortezomib before.
São Paulo, São PauloAges 16–60 - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07025564RecruitingPhase 1
MiRisten for relapsed or refractory AML
This phase 1 trial tests a new treatment called MiRisten for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Rochester, MinnesotaAges 18 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Peoria, IllinoisAges 18 years+ - NCT06920199RecruitingEarly Phase 1
Donor Treg cells plus IL-2 for stubborn chronic GVHD
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
ShanghaiAges 18–70 - NCT06902792Enrolling by invitationPhase 1
Adebrelimab and trametinib for children with hard-to-treat LCH
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Wenzhou, ZhejiangAges Up to 18 years - NCT06894602Recruiting
Can Ultrasound Predict Relapse in Giant Cell Arteritis?
This study uses an ultrasound of the temporal artery (a vessel in your temple) to see if certain findings can predict whether giant cell arteritis will come back. It may help doctors know who needs closer monitoring.
BrestAges 18 years+ - NCT06865664RecruitingPhase 1
Engineered immune cells for relapsed rhabdomyosarcoma in youth
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Bethesda, MarylandAges 3–39 - NCT06847269RecruitingPhase 2
CAR T cell therapy for children and young adults with CD19+ leukemia
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
Memphis, TennesseeAges Up to 21 years - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06777979RecruitingPhase 1
CAR T cell therapy for children with hard-to-treat leukemia
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
Memphis, TennesseeAges Up to 21 years - NCT06458257Recruiting
Stem cell transplant for high-risk AML with CEBPA mutation
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06418789RecruitingPhase 2
High-dose chemo for relapsed germ cell tumors
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
Saint Petersburg, Russian FederationAges 18 years+ - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT04629833RecruitingPhase 3
Mesenchymal cells vs standard care for steroid-resistant graft-versus-host disease
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
AmiensAges 12 years+ - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell lymphoma?
- Yes. Clin2 currently lists 1,718 recruiting relapsed or refractory b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- Relapsed or Refractory Peripheral T Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.